Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Heptares Therapeutics Ltd.

Division of Sosei Heptares
www.soseiheptares.com

Latest From Heptares Therapeutics Ltd.

Venture Funding Deals: Spin-Outs From Axovant, Inovio & Sosei

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced January and February 2019.

Deals Financing

Deal Watch: Xencor Adds New Bispecific Partner In Agreement With Genentech

Genentech will pay $120m up front to co-develop Xencor’s preclinical IL-15 candidate; deal also includes IL-15 R&D. Taiho licenses lung cancer candidate to Cullinan; Celgene and Triphase partner again.

Deals Business Strategies

Medicxi Links With Sosei Heptares For Orexin Agonist Vehicles

After spending 12 months looking for promising orexin agonist candidates, asset-centric venture capitalist Medicxi finds answer close to home and commits up to €40M to create two companies underpinned by assets from Heptares Therapeutics.

Neurology Commercial

OMass Therapeutics Pivots From Services To Drug Discovery With Novel Mass Spect Technology

The UK start-up has quickly switched from research services to drug discovery to exploit more fully its novel platform technology for drug screening and development, funded by Syncona and other investors.

 

StartUps and SMEs Platform Technologies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Sosei Heptares
  • Senior Management
  • Malcolm Weir, PhD, Chmn. & CEO
    Fiona Marshall , PhD, CSO
    Barry Kenny, PhD, Chief Business Officer
    Tim Tasker, MD, VP, Dev. & CMO
    Ali Jazayeri, CTO
  • Contact Info
  • Heptares Therapeutics Ltd.
    Phone: (44) 1707 358 628
    BioPark
    Broadwater Rd.
    Welwyn Garden City, AL7 3AX
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register